Last reviewed · How we verify
HM12470
At a glance
| Generic name | HM12470 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470 (PHASE1)
- Molar Potency Study of HM12470 in Healthy Subjects (PHASE1)
- Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HM12470 CI brief — competitive landscape report
- HM12470 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI